Through a subsidiary, Catalent said, it will soon commence a tender offer to purchase all of Juniper's shares at $11.50 per share, net to the seller in cash. That's a 32% premium over Juniper's closing stock price yesterday of $8.70, and is a nickel per share above the $11.45 to which Juniper shares climbed in premarket trading this morning as of 8:44 a.m. "Catalent's offer to acquire Juniper recognizes the value of Juniper's businesses, Juniper Pharma Services, and Crinone," stated Alicia Secor, Juniper's president and CEO, in a separate statement issued by her company. Following the conclusion of the tender offer, Catalent said, it intends to complete the transaction by acquiring the remainder of the Juniper shares at the same price through a merger with a newly formed, wholly owned subsidiary of Catalent. The deal is set to be completed later this quarter—the first quarter of Catalent's 2019 fiscal year, which began on Sunday.